Nadav Kidron is the CEO of Oramed Pharmaceuticals, a company focused on developing oral insulin treatments for type 2 diabetes. Based in Jerusalem, Israel.
Nadav Kidron is the CEO of Oramed Pharmaceuticals, a company focused on developing oral insulin treatments for type 2 diabetes. In 2017, Oramed successfully positioned itself to initiate a U.S.-based multicenter 90-day treatment study for lowering HbA1c in type 2 diabetic patients. The company also began a dual listing on the Tel Aviv Stock Exchange and received approval from the Israel Ministry of Health for two exploratory human trials for NASH and Leptin. Kidron relocated to Oramed's NYC office in 2017.
Full founder directory · Investor directory · Company funding database · Fundraising library